

References

Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer. Isaakidou A, Gazouli M, Aravantinos G, Pectasides D, Theodoropoulos GE. *J Cancer Res Ther.* 2016 Jan-Mar;12(1):193-7. doi: 10.4103/0973-1482.148654. PMID: 27072236

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. Aravantinos G, Pectasides D. *J Ovarian Res.* 2014 May 19;7:57. doi: 10.1186/1757-2215-7-57. eCollection 2014. Review. PMID: 24864163

Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue. Lyberopoulou A, Aravantinos G, Efstathopoulos EP, Nikiteas N, Bouziotis P, Isaakidou A, Papalois A, Marinos E, Gazouli M. *PLoS One.* 2015 Apr 22;10(4):e0123902. doi: 10.1371/journal.pone.0123902. eCollection 2015. PMID: 25902072

Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. Kalofonos HP, Papakostas P, Makatsoris T, Papamichael D, Vourli G, Xanthakis I, Aravantinos G, Papadimitriou C, Pentheroudakis G, Varthalitis I, Samelis G, Syrigos KN, Xiros N, Stavropoulos M, Kosmidis P, Christodoulou C, Linardou H, Skondra M, Pectasides D, Economopoulos T, Fountzilas G. *Anticancer Res.* 2010 Oct;30(10):4325-33. PMID: 21036759

Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. Kotoula V, Karavasilis V, Zagouri F, Kouvatseas G, Giannoulatou E, Gogas H, Lakis S, Pentheroudakis G, Bobos M, Papadopoulou K, Tsolaki E, Pectasides D, Lazaridis G, Koutras A, Aravantinos G, Christodoulou C, Papakostas P, Markopoulos C, Zografos G, Papandreou C, Fountzilas G. *Breast Cancer Res Treat.* 2016 Jul;158(2):307-21. doi: 10.1007/s10549-016-3883-z. Epub 2016 Jul 1. PMID: 27369359

Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Aravantinos G, Fountzilas G, Bamias A, Grimani I, Rizos S, Kalofonos HP, Skarlos DV, Economopoulos T, Kosmidis PA, Stathopoulos GP, Briasoulis E, Pectasides D, Samantas E, Timotheadou E, Papadimitriou C, Papanikolaou A, Onyenadum A, Papakostas P, Bafaloukos D, Dimopoulos MA; Hellenic Cooperative Oncology Group study. *Eur J Cancer.* 2008 Oct;44(15):2169-77. doi: 10.1016/j.ejca.2008.06.035. Epub 2008 Aug 6. PMID: 18691879

Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial. Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, Gourgioti G, Gakou C, Syrigos KN, Bournakis E, Rallis G, Varthalitis I, Galani E, Lazaridis G, Papaxoinis G, Pectasides D, Aravantinos G, Makatsoris T, Kalogeras KT, Fountzilas G. *PLoS One.* 2015 May 13;10(5):e0124612. doi: 10.1371/journal.pone.0124612. eCollection 2015. PMID: 25970543

Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of

erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia. Mountzios G, Aravantinos G, Alexopoulou Z, Timotheadou E, Matsiakou F, Christodoulou C, Laschos K, Galani E, Koutras A, Bafaloukos D, Linardou H, Pectasides D, Varthalitis I, Papakostas P, Kalofonos HP, Fountzilias G. *Mol Clin Oncol*. 2016 Feb;4(2):211-220. Epub 2015 Dec 4. PMID:26893865

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. Papaxoinis G, Kotoula V, Alexopoulou Z, Kalogeras KT, Zagouri F, Timotheadou E, Gogas H, Pentheroudakis G, Christodoulou C, Koutras A, Bafaloukos D, Aravantinos G, Papakostas P, Charalambous E, Papadopoulou K, Varthalitis I, Efstratiou I, Zaramboukas T, Patsea H, Scopa CD, Skondra M, Kosmidis P, Pectasides D, Fountzilias G. *PLoS One*. 2015 Oct 9;10(10):e0140293. doi: 10.1371/journal.pone.0140293. eCollection 2015. PMID: 26452060

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. Gogas H, Kotoula V, Alexopoulou Z, Christodoulou C, Kostopoulos I, Bobos M, Raptou G, Charalambous E, Tsolaki E, Xanthakis I, Pentheroudakis G, Koutras A, Bafaloukos D, Papakostas P, Aravantinos G, Psyrris A, Petraki K, Kalogeras KT, Pectasides D, Fountzilias G. *J Transl Med*. 2016 May 17;14(1):136. doi: 10.1186/s12967-016-0883-z. PMID: 27184134

Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N, Economopoulos T, Raptis SA. *Eur Urol*. 2004 Aug;46(2):216-21. PMID: 15245816

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA, Pentheroudakis G, Samantas E, Bamias A, Miliaras D, Basdanis G, Xiros N, Klouvas G, Bafaloukos D, Kafiri G, Papaspirou I, Pectasides D, Karanikiotis C, Economopoulos T, Efstratiou I, Korantzis I, Pisanidis N, Makatsoris T, Matsiakou F, Aravantinos G, Kalofonos HP, Fountzilias G. *BMC Med*. 2011 Jan 31;9:10. doi: 10.1186/1741-7015-9-10. PMID: 21281463

Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study. Kourea HP, Kotoula V, Koutras A, Alexopoulou Z, Papaspirou I, Skarlos DV, Efstratiou I, Bobos M, Zagouri F, Papakostas P, Pectasides D, Chrisafi S, Varthalitis I, Aravantinos G, Kosmidis P, Bafaloukos D, Scopa CD, Fountzilias G. *Histol Histopathol*. 2015 Sep;30(9):1129-41. doi: 10.14670/HH-11-612. Epub 2015 Mar 25. PMID: 25807307

Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer. Liarmakopoulos E, Gazouli M, Aravantinos G, Tzanakis N, Theodoropoulos G, Rizos S, Nikiteas N. *Gastric Cancer*. 2011 Oct;14(4):317-21. doi: 10.1007/s10120-011-0045-1. Epub 2011 Apr 2. PMID: 21461653

Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. Kosmidis PA, Dimopoulos MA, Syrigos K, Nicolaidis C, Aravantinos G, Boukovinas I, Pectasides D, Fountzilias G, Bafaloukos D, Bacoyiannis C, Kalofonos HP. *J Thorac Oncol*. 2007 Feb;2(2):135-40. PMID: 17410029

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A, Fountzilas G, Kalofonos HP, Kosmidis P, Timotheadou E, Makatsoris T, Samantas E, Briasoulis E, Christodoulou C, Papakostas P, Pectasides D, Dimopoulos AM. *BMC Med.* 2010 Jan 7;8:3. doi: 10.1186/1741-7015-8-3. PMID: 20055981

Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. Lakis S, Dimoudis S, Kotoula V, Alexopoulou Z, Kostopoulos I, Koletsa T, Bobos M, Timotheadou E, Papaspirou I, Efstratiou I, Aravantinos G, Karavasilis V, Zagouri F, Gogas H, Razis E, Pentheroudakis G, Christodoulou C, Pectasides D, Fountzilas G. *Anticancer Res.* 2016 May;36(5):2365-78. PMID: 27127145

Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Pentheroudakis G, Fountzilas G, Kalofonos HP, Golfopoulos V, Aravantinos G, Bafaloukos D, Papakostas P, Pectasides D, Christodoulou C, Syrigos K, Economopoulos T, Pavlidis N; Hellenic Cooperative Oncology Group. *Crit Rev Oncol Hematol.* 2008 Jun;66(3):237-47. doi: 10.1016/j.critrevonc.2007.12.003. Epub 2008 Feb 1. PMID: 18243010

Genetic polymorphisms of interleukin 1 β gene and sporadic pancreatic neuroendocrine tumors susceptibility. Karakaxas D, Sioziou A, Aravantinos G, Coker A, Papanikolaou IS, Liakakos T, Dervenis C, Gazouli M. *World J Gastrointest Oncol.* 2016 Jun 15;8(6):520-5. doi: 10.4251/wjgo.v8.i6.520. PMID: 27326321

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. Koutras A, Kalogeras KT, Wirtz RM, Alexopoulou Z, Bobos M, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Pentheroudakis G, Pisanidis N, Magkou C, Christodoulou C, Bafaloukos D, Papakostas P, Aravantinos G, Pectasides D, Kalofonos HP, Fountzilas G. *J Transl Med.* 2015 May 29;13:171. doi: 10.1186/s12967-015-0530-0. PMID: 26021752

Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. Stavropoulou AV, Fostira F, Pertesi M, Tsitlaidou M, Voutsinas GE, Triantafyllidou O, Bamias A, Dimopoulos MA, Timotheadou E, Pectasides D, Christodoulou C, Klouvas G, Papadimitriou C, Makatsoris T, Pentheroudakis G, Aravantinos G, Karydakis V, Yannoukakos D, Fountzilas G, Konstantopoulou I. *PLoS One.* 2013;8(3):e58182. doi: 10.1371/journal.pone.0058182. Epub 2013 Mar 11. Erratum in: *PLoS One.* 2013;8(4). doi:10.1371/annotation/159f0ba3-5a24-4de9-99be-1cd6d5037760. PMID: 23536787

Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Skarlos DV, Kalofonos HP, Fountzilas G, Dimopoulos MA, Pavlidis N, Razis E, Economopoulos T, Pectasides D, Gogas H, Kosmidis P, Bafaloukos D, Klouvas G, Kyrtzidis G, Aravantinos G. *Anticancer Res.* 2005 Jul-Aug;25(4):3103-8. PMID: 16080573

Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study. Pectasides D, Papaxoinis G, Kotoula V, Fountzilas H, Korantzis I, Koutras A, Dimopoulos AM, Papakostas P, Aravantinos G, Varthalitis I, Kosmidis P, Skarlos D, Bournakis E, Bafaloukos D, Kalofonos HP,

Kalogeras KT, Fountzilias G. *Oncol Rep.* 2012 Jan;27(1):216-24. doi: 10.3892/or.2011.1504. Epub 2011 Oct 13. PMID: 22025320

Effects of stromal cell-derived factor-1 and survivin gene polymorphisms on gastric cancer risk. Liarmakopoulos E, Theodoropoulos G, Vaiopoulou A, Rizos S, Aravantinos G, Kouraklis G, Nikiteas N, Gazouli M. *Mol Med Rep.* 2013 Mar;7(3):887-92. doi: 10.3892/mmr.2012.1247. Epub 2012 Dec 21. PMID: 23258739

E-Selectin S128R gene polymorphism in gastric cancer. Liarmakopoulos E, Gazouli M, Aravantinos G, Theodoropoulos G, Rizos S, Vaiopoulou A, Kouraklis G, Nikiteas N. *Int J Biol Markers.* 2013 Apr 23;28(1):38-42. doi: 10.5301/JBM.2012.9582. PMID: 23015400

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Kotoula V, Chatzopoulos K, Lakis S, Alexopoulou Z, Timotheadou E, Zagouri F, Pentheroudakis G, Gogas H, Galani E, Efstratiou I, Zaramboukas T, Koutras A, Aravantinos G, Samantas E, Psyrris A, Kourea H, Bobos M, Papakostas P, Kosmidis P, Pectasides D, Fountzilias G. *Oncotarget.* 2016 Jan 26;7(4):5074-87. doi: 10.18632/oncotarget.6231. PMID: 26506242

Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Pectasides D, Aravantinos G, Fountzilias G, Kalofonos C, Efsthathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA. *Anticancer Res.* 2005 Sep-Oct;25(5):3553-8. Review. PMID: 16101179

Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma. Pectasides D, Xiros N, Papaxoinis G, Aravantinos G, Sykiotis C, Pectasides E, Psyrris A, Koumariou A, Gaglia A, Gouveris P, Economopoulos T. *Gynecol Oncol.* 2008 Jan;108(1):47-52. Epub 2007 Oct 25. PMID: 17915300

Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Tzaida O, Gogas H, Dafni U, Kyroudi A, Papaspyrou I, Kyriakou V, Malamou-Mitsi V, Alamani M, Skopa C, Kostopoulos I, Kastritis E, Pectasides D, Briasoulis E, Kalofonos HP, Aravantinos G, Fountzilias G, Arapantoni-Dadioti P. *Oncology.* 2007;72(5-6):388-96. doi: 10.1159/000113148. Epub 2008 Jan 14. PMID: 18187961

PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. Koumariou A, Karayannopoulou G, Gourgioti G, Batistatou A, Bobos M, Efstratiou I, Miliaras D, Galani E, Pentheroudakis G, Pectasides D, Aravantinos G, Bafaloukos D, Papakostas P, Razis E, Kalofonos HP, Petraki K, Sotiropoulou M, Kalogeras KT, Fountzilias G. *Cancer Chemother Pharmacol.* 2015 Jun;75(6):1289-301. doi: 10.1007/s00280-015-2762-3. Epub 2015 May 7. PMID: 25947084

Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study. Makatsoris T, Papakostas P, Kalofonos HP, Xanthakis I, Tsavdaridis D, Aravantinos G, Gogas H, Klouvas G, Kosmidis P, Pectasides D, Fountzilias G. *Med Oncol.* 2007;24(3):301-7. PMID: 17873305

Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. Pectasides D, Skarlos D, Dimopoulos AM, Farmakis D, Pectasides M, Fountzilias G, Aravantinos G. *Anticancer Res.* 2003 Sep-Oct;23(5b):4239-44. PMID: 14666633

Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Razis E, Kalogeras KT, Kotoula V, Eleftheraki AG, Nikitas N, Kronenwett R, Timotheadou E, Christodoulou C, Pectasides D, Gogas H, Wirtz RM, Makatsoris T, Bafaloukos D, Aravantinos G, Televantou D, Pavlidis N, Fountzilias G. *Clin Breast Cancer.* 2012 Jun;12(3):183-93. doi: 10.1016/j.clbc.2012.03.006. Erratum in: *Clin Breast Cancer.* 2012 Oct;12(5):386. PMID: 22607768

Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Pectasides D, Fountzilias G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, Dimopoulos MA. *Gynecol Oncol.* 2005 May;97(2):436-41. PMID: 15863142

Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, Fountzilias G. *Oncology.* 2009;77(2):107-12. doi: 10.1159/000229504. Epub 2009 Jul 21. PMID: 19622901

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. Fountzilias G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R, Wirtz RM, Bobos M, Timotheadou E, Soupos N, Pentheroudakis G, Gogas H, Vlachodimitropoulos D, Polychronidou G, Aravantinos G, Koutras A, Christodoulou C, Pectasides D, Arapantoni P. *J Transl Med.* 2012 Jan 12;10:10. doi: 10.1186/1479-5876-10-10. PMID: 22240029

Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study. Sgouros J, Aravantinos G, Kouvatseas G, Rapti A, Stamoulis G, Bisvikis A, Res H, Samantas E. *J Gastrointest Cancer.* 2015 Dec;46(4):343-9. doi: 10.1007/s12029-015-9746-8. PMID: 26143067

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. Negru S, Papadopoulou E, Apessos A, Stanculeanu DL, Ciuleanu E, Volovat C, Croitoru A, Kakolyris S, Aravantinos G, Ziras N, Athanasiadis E, Touroutoglou N, Pavlidis N, Kalofonos HP, Nasioulas G. *BMJ Open.* 2014 May 23;4(5):e004652. doi: 10.1136/bmjopen-2013-004652. PMID: 24859998

Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Androulakis N, Syrigos K, Polyzos A, Aravantinos G, Stathopoulos GP, Ziras N, Mallas K, Vamvakas L, Georgoulis V; Hellenic Oncology Research Group. *Cancer Invest.* 2005;23(1):9-12. PMID: 15779862

Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients. Papadopoulou E, Tsoulos N, Tsirigoti A, Apessos A, Agiannitopoulos K, Metaxa-Mariatou V, Zarogoulidis K, Zarogoulidis P, Kasarakis D, Kakolyris S, Dahabreh J, Vlastos F, Zoublios C, Rapti A, Papageorgiou NG, Veldekis D, Gaga M, Aravantinos G, Karavasilis V,

Karagiannidis N, Nasioulas G. *Oncol Lett.* 2015 Oct;10(4):2176-2184. Epub 2015 Aug 12. PMID: 26622815

Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Androulakis N, Aravantinos G, Syrigos K, Polyzos A, Ziras N, Tselepatiotis E, Samonis G, Kentepozidis N, Giassas S, Vamvakas L, Georgoulas V. *Oncology.* 2006;70(4):280-4. Epub 2006 Oct 12. PMID: 17047399

Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Janinis J, Stathopoulos GP, Nikolaidis P, Kalofonos HP, Kalogera-Fountzila A, Samantas E, Aravantinos G, Anagnostopoulos A, Tolis C, Makatsoris T, Rigatos SK, Bafaloukos D, Dimopoulos MA, Daniilidis J, Fountzilas G. *Anticancer Drugs.* 2004 Jun;15(5):479-87. PMID: 15166622

Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. Karavasilis V, Papadimitriou C, Gogas H, Kouvatsas G, Pentheroudakis G, Koutras A, Christodoulou C, Bafaloukos D, Samantas E, Pisanidis N, Papakostas P, Aravantinos G, Karanikiotis C, Kosmidis P, Pectasides D, Dimopoulos MA, Fountzilas G. *Clin Breast Cancer.* 2016 Aug;16(4):291-298.e3. doi: 10.1016/j.clbc.2015.12.001. Epub 2015 Dec 17. PMID: 26791750

The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. Samelis GF, Kalofonos H, Adamou A, Kosmides P, Skarlos D, Aravantinos G, Kiamouris C, Adimchi O, Fountzilas G, Dimopoulos AM. *Urology.* 2005 Aug;66(2):382-5. PMID: 16098366

A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. Makatsoris T, Kalofonos HP, Aravantinos G, Papadimitriou C, Kastiris E, Rigatos SK, Xiros N, Petsas T, Economopoulos T, Sakadamis AK, Fountzilas G; Hellenic Cooperative Oncology Group. *Int J Gastrointest Cancer.* 2005;35(2):103-9. PMID: 15879624

Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Stravopodis DJ, Karkoulis PK, Konstantakou EG, Melachroinou S, Lampidonis AD, Anastasiou D, Kachrilas S, Messini-Nikolaki N, Papassideri IS, Aravantinos G, Margaritis LH, Voutsinas GE. *Int J Oncol.* 2009 Jan;34(1):137-60. PMID: 19082486

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Panoilia E, Schindler E, Samantas E, Aravantinos G, Kalofonos HP, Christodoulou C, Patrinos GP, Friberg LE, Sivolapenko G. *Cancer Chemother Pharmacol.* 2015 Apr;75(4):791-803. doi: 10.1007/s00280-015-2701-3. Epub 2015 Feb 17. PMID: 25687989

Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells. Stravopodis DJ, Karkoulis PK, Konstantakou EG, Melachroinou S, Thanasopoulou A, Aravantinos G, Margaritis LH, Anastasiadou E, Voutsinas GE. *J Cancer Res Clin Oncol.* 2011 Feb;137(2):359-74. doi: 10.1007/s00432-010-0891-y. Epub 2010 Apr 28. PMID: 20425122

Comparison of HER2 detection methods between central and regional laboratories in Greece. Papadopoulou S, Kouvatsas G, Skarlos D, Malamos N, Delliou E, Saratsiotou I, Ardavanis A,

Mavroudis D, Skarpidi E, Arapantoni P, Karyda I, Patakioyta F, Aravantinos G, Razis E, Fountzilias G, Kosmidis P. Clin Breast Cancer. 2007 Oct;7(10):784-90. PMID: 18021480
Aims, design and methods of a case-control study for the assessment of the role of dietary habits, eating behaviors and environmental factors, on the development of breast cancer. Mourouti N, Papavagelis C, Psaltopoulou T, Aravantinos G, Samantas E, Filopoulos E, Manousou A, Plytzanopoulou P, Vassilakou T, Malamos N, Panagiotakos DB. Maturitas. 2013 Jan;74(1):31-6. doi: 10.1016/j.maturitas.2012.10.004. Epub 2012 Nov 3. PMID: 23131812

MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Fountzilias G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D. J Oncol. 2009;2009:305908. doi: 10.1155/2009/305908. Epub 2009 Dec 29. PMID: 20066159

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias A, Fountzilias G. Cancer Invest. 2008 Jun;26(5):491-8. doi: 10.1080/07357900701829785. PMID: 18568771

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, Makatsoris T, Varthalitis I, Xanthakis I, Vassias A, Klouvas G, Boukovinas I, Fountzilias G, Syrigos KN, Kalofonos H, Samantas E. BMC Cancer. 2013 May 29;13:263. doi: 10.1186/1471-2407-13-263. PMID: 23718900

Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Konstantakou EG, Voutsinas GE, Karkoulis PK, Aravantinos G, Margaritis LH, Stravopodis DJ. Int J Oncol. 2009 Aug;35(2):401-16. PMID: 19578756

Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG). Timotheadou E, Papakostas P, Tsavdaridis D, Basdanis G, Kalofonos H, Aravantinos G, Bafaloukos D, Fountzilias G. Tumori. 2005 Jul-Aug;91(4):309-13. PMID: 16277094

A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Kalofonos HP, Nicolaidis C, Samantas E, Mylonakis N, Aravantinos G, Dimopoulos MA, Gennatas C, Kouvatseas G, Giannoulis E, Dervenis C, Basdanis G, Pavlidis N, Androulakis I, Fountzilias G; Hellenic Cooperative Oncology Group (HeCOG). Am J Clin Oncol. 2002 Feb;25(1):23-30. PMID: 11823690

Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17. Kotoula V, Bobos M, Alexopoulou Z, Papadimitriou C, Papadopoulou K, Charalambous E, Tsolaki E, Xepapadakis G, Nicolaou I, Papaspirou I, Aravantinos G, Christodoulou C, Efstratiou I, Gogas H, Fountzilias G. PLoS One. 2014 Aug 6;9(8):e103707. doi: 10.1371/journal.pone.0103707. eCollection 2014. PMID: 25098819

Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. Batistatou A, Kotoula V, Bobos M, Kouvatseas G, Zagouri F, Tsolaki E, Gogas H, Koutras A, Pentheroudakis G, Timotheadou E, Pervana S, Goussia A, Petraki K, Sotiropoulou M, Koletsa T, Razis E, Kosmidis P, Aravantinos G, Papadimitriou C, Pectasides D, Fountzilias G. *Clin Breast Cancer*. 2017 Jul 13. pii: S1526-8209(17)30138-6. doi: 10.1016/j.clbc.2017.07.004. [Epub ahead of print] PMID: 28870680

Protein expression patterns of cell cycle regulators in operable breast cancer. Zagouri F, Kotoula V, Kouvatseas G, Sotiropoulou M, Koletsa T, Gavressea T, Valavanis C, Trihia H, Bobos M, Lazaridis G, Koutras A, Pentheroudakis G, Skarlos P, Bafaloukos D, Arnogiannaki N, Chrisafi S, Christodoulou C, Papakostas P, Aravantinos G, Kosmidis P, Karanikiotis C, Zografos G, Papadimitriou C, Fountzilias G. *PLoS One*. 2017 Aug 10;12(8):e0180489. doi:10.1371/journal.pone.0180489. eCollection 2017. PMID: 28797035

Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Timotheadou E, Kalogeras KT, Koliou GA, Wirtz RM, Zagouri F, Koutras A, Veltrup E, Christodoulou C, Pentheroudakis G, Tsiftoglou A, Papakostas P, Aravantinos G, Venizelos V, Pectasides D, Kosmidis P, Karanikiotis C, Markopoulos C, Gogas H, Fountzilias G. *Transl Oncol*. 2017 Aug;10(4):589-598. doi: 10.1016/j.tranon.2017.05.006. Epub 2017 Jun 27. PMID: 28666187

The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. Gavressea T, Kalogeras KT, Koliou GA, Zagouri F, Lazaridis G, Gogas H, Tsigaridas K, Koutras A, Petraki K, Markopoulos C, Pazarli E, Aravantinos G, Papadimitriou C, Papakostas P, Koufopoulos N, Karanikiotis C, Chrisafi S, Kalofonos HP, Pectasides D, Fountzilias G, Pavlakis K. *Anticancer Res*. 2017 Jun;37(6):2947-2957. PMID: 28551632

Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer. Strati TM, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Lazaridis G, Lakis S, Pentheroudakis G, Pectasides D, Pazarli E, Christodoulou C, Razis E, Pavlakis K, Magkou C, Chrisafi S, Aravantinos G, Bafaloukos D, Papakostas P, Gogas H, Kalogeras KT, Fountzilias G. *Anticancer Res*. 2017 May;37(5):2323-2334. PMID: 28476798

Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. Levva S, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Papadopoulou K, Lakis S, Koukoulis K, Karavasilis V, Pentheroudakis G, Balassi E, Zagouri F, Kaklamanos IG, Pectasides D, Razis E, Aravantinos G, Papakostas P, Bafaloukos D, Rallis G, Gogas H, Fountzilias G. *Cancer Genomics Proteomics*. 2017 May-Jun;14(3):181-195. PMID: 28446533

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC Jr, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N; AOCs study group, Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ,

Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlersen B, Ekici AB, Ellis S, Elvira M; EMBRACE Study, Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A; GEMO Study Collaborators, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harrington PA, Harris HR, Hauke J; HEBON Study, Hein A, Henderson A, Hildebrandt MAT, Hillemanns P, Hodgson S, Høgdall CK, Høgdall E, Hogervorst FBL, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Hunter DJ, Huntsman DG, Huzarski T, Imyanitov EN, Isaacs C, Iversen ES, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jernetz M, Jensen A, Jensen UB, John EM, Johnatty S, Jones ME, Kannisto P, Karlan BY, Karnezis A, Kast K; KConFab Investigators, Kennedy CJ, Khusnutdinova E, Kiemeny LA, Kiiski JI, Kim SW, Kjaer SK, Köbel M, Kopperud RK, Kruse TA, Kupryjanczyk J, Kwong A, Laitman Y, Lambrechts D, Larrañaga N, Larson MC, Lazaro C, Le ND, Le Marchand L, Lee JW, Lele SB, Leminen A, Leroux D, Lester J, Lesueur F, Levine DA, Liang D, Liebrich C, Lilyquist J, Lipworth L, Lissowska J, Lu KH, Lubinński J, Luccarini C, Lundvall L, Mai PL, Mendoza-Fandiño G, Manoukian S, Massuger LFAG, May T, Mazoyer S, McAlpine JN, McGuire V, McLaughlin JR, McNeish I, Meijers-Heijboer H, Meindl A, Menon U, Mensenkamp AR, Merritt MA, Milne RL, Mitchell G, Modugno F, Moes-Sosnowska J, Moffitt M, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Nathanson KL, Nedergaard L, Ness RB, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Odunsi K, Olah E, Olopade OI, Olsson H, Olswold C, O'Malley DM, Ong KR, Onland-Moret NC; OPAL study group, Orr N, Orsulic S, Osorio A, Palli D, Papi L, Park-Simon TW, Paul J, Pearce CL, Pedersen IS, Peeters PHM, Peissel B, Peixoto A, Pejovic T, Pelttari LM, Permut JB, Peterlongo P, Pezzani L, Pfeiler G, Phillips KA, Piedmonte M, Pike MC, Piskorz AM, Poblete SR, Pocza T, Poole EM, Poppe B, Porteous ME, Prieur F, Prokofyeva D, Pugh E, Pujana MA, Pujol P, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rhiem K, Rice P, Richardson A, Robson M, Rodriguez GC, Rodríguez-Antona C, Romm J, Rookus MA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Salvesen HB, Sandler DP, Schoemaker MJ, Senter L, Setiawan VW, Severi G, Sharma P, Shelford T, Siddiqui N, Side LE, Sieh W, Singer CF, Sobol H, Song H, Southey MC, Spurdle AB, Stadler Z, Steinemann D, Stoppa-Lyonnet D, Sucheston-Campbell LE, Sukiennicki G, Sutphen R, Sutter C, Swerdlow AJ, Szabo CI, Szafron L, Tan YY, Taylor JA, Tea MK, Teixeira MR, Teo SH, Terry KL, Thompson PJ, Thomsen LCV, Thull DL, Tihomirova L, Tinker AV, Tischkowitz M, Tognazzo S, Toland AE, Tone A, Trabert B, Travis RC, Trichopoulou A, Tung N, Tworoger SS, van Altena AM, Van Den Berg D, van der Hout AH, van der Luijt RB, Van Heetvelde M, Van Nieuwenhuysen E, van Rensburg EJ, Vanderstichele A, Varon-Mateeva R, Vega A, Edwards DV, Vergote I, Vierkant RA, Vijai J, Vratimos A, Walker L, Walsh C, Wand D, Wang-Gohrke S, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, Whittemore AS, Wijnen JT, Wilkens LR, Wolk A, Woo M, Wu X, Wu AH, Yang H, Yannoukakos D, Ziogas A, Zorn KK, Narod SA, Easton DF, Amos CI, Schildkraut JM, Ramus SJ, Ottini L, Goodman MT, Park SK, Kelemen LE, Risch HA, Thomassen M, Offit K, Simard J, Schmutzler RK, Hazelett D, Monteiro AN, Couch FJ, Berchuck A, Chenevix-Trench G, Goode EL, Sellers TA, Gayther SA, Antoniou AC, Pharoah

PDP. *Nat Genet.* 2017 May;49(5):680-691. doi: 10.1038/ng.3826. Epub 2017 Mar 27. PMID: 28346442

Identification of Methylation Profiles of Cancer-related Genes in Circulating Tumor Cells Population. Lyberopoulou A, Galanopoulos M, Aravantinos G, Theodoropoulos GE, Marinou E, Efsthopoulos EP, Gazouli M. *Anticancer Res.* 2017 Mar;37(3):1105-1112. PMID: 28314271

Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. Psyrris A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Koutras A, Lazaridis G, Christodoulou C, Pentheroudakis G, Economopoulou P, Laskarakis A, Arapantoni-Dadioti P, Batistatou A, Sotiropoulou M, Aravantinos G, Papakostas P, Kosmidis P, Pectasides D, Fountzilias G. *J Transl Med.* 2017 Feb 13;15(1):30. doi: 10.1186/s12967-017-1134-7. PMID: 28193231

Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. Stavridi F, Kalogeras KT, Pliarchopoulou K, Wirtz RM, Alexopoulou Z, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Koutras A, Lazaridis G, Christodoulou C, Pentheroudakis G, Laskarakis A, Arapantoni-Dadioti P, Batistatou A, Sotiropoulou M, Aravantinos G, Papakostas P, Kosmidis P, Pectasides D, Fountzilias G. *PLoS One.* 2016 Oct 3;11(10):e0164013. doi: 10.1371/journal.pone.0164013. eCollection 2016. PMID: 27695115

Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. Kotoula V, Lakis S, Vlachos IS, Giannoulatou E, Zagouri F, Alexopoulou Z, Gogas H, Pectasides D, Aravantinos G, Efstratiou I, Pentheroudakis G, Papadopoulou K, Chatzopoulos K, Papakostas P, Sotiropoulou M, Nicolaou I, Razis E, Psyrris A, Kosmidis P, Papadimitriou C, Fountzilias G. *PLoS One.* 2016 Sep 29;11(9):e0163138. doi: 10.1371/journal.pone.0163138. eCollection 2016. PMID: 27685159

Cost-Effectiveness Analysis Of Granulocyte Colony-Stimulating Factors For The Prophylaxis Of Chemotherapy-Induced Febrile Neutropenia In Patients With Breast Cancer In Greece. Kourlaba G, Gourzoulidis G, Aravantinos G, Athanasiadis I, Lyman GH, Villa G, Papagiannopoulou V, Tritaki G, Maniadas N. *Value Health.* 2015 Nov;18(7):A456. doi: 10.1016/j.jval.2015.09.1166. Epub 2015 Oct 20. No abstract available. PMID:26532561

Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer. Aravantinos G, Isaakidou A, Karantanos T, Sioziou A, Theodoropoulos GE, Pektasides D, Gazouli M. *Cancer Biomark.* 2015;15(6):843-50. doi: 10.3233/CBM-150528. PMID: 26406410

European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015. du Bois A, Reuss A, Pujade-Lauraine E, Pignata S, Ledermann J, Casado A, Sehouli J, Mirza M, Colombo N, Marth C, Witteveen E, Del Campo J, Calvert P, Aravantinos G, Vardar MA, van der Zee AG, Korach J, Taskiran C, Fehr M, Glasspool R, Pfisterer J, Cibula D, Vergote I; member trial groups of the European Network of Gynaecological Oncological Trial Groups (ENGOT). *Int J Gynecol Cancer.* 2015 Sep;25(7):1328-30. doi: 10.1097/IGC.000000000000478. PMID: 26067859

Maintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence. Stathopoulos GP, Papadimitriou Ch, Aravantinos G, Rigatos SK, Malamos N,

Stathopoulos JG, Kaparelou M, Koutantos J, Andreadis Ch. J BUON. 2012 Oct-Dec;17(4):735-9. PMID: 23335534

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Bamias A, Dafni U, Karadimou A, Timotheadou E, Aravantinos G, Psyrri A, Xanthakis I, Tsiatas M, Koutoulidis V, Constantinidis C, Hatzimouratidis C, Samantas E, Visvikis A, Chrisophos M, Stravodimos K, Deliveliotis C, Eleftheraki A, Pectasides D, Fountzilias G, Dimopoulos MA. Ann Oncol. 2013 Apr;24(4):1011-7. doi: 10.1093/annonc/mds583. Epub 2012 Nov 7. PMID: 23136231

Development of a quantum-dot-labelled magnetic immunoassay method for circulating colorectal cancer cell detection. Gazouli M, Lyberopoulou A, Pericleous P, Rizos S, Aravantinos G, Nikiteas N, Anagnou NP, Efsthathopoulos EP. World J Gastroenterol. 2012 Aug 28;18(32):4419-26. doi: 10.3748/wjg.v18.i32.4419. PMID: 22969208

Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Psyrri A, Kalogeras KT, Kronenwett R, Wirtz RM, Batistatou A, Bournakis E, Timotheadou E, Gogas H, Aravantinos G, Christodoulou C, Makatsoris T, Linardou H, Pectasides D, Pavlidis N, Economopoulos T, Fountzilias G. Ann Oncol. 2012 Jun;23(6):1422-7. doi: 10.1093/annonc/mdr527. Epub 2011 Nov 4. PMID: 22056852

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilias G. Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8. PMID: 21901395

Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Fountzilias G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, Papazisis KT, Timotheadou E, Efstratiou I, Koutras A, Pentheroudakis G, Christodoulou C, Aravantinos G, Miliaras D, Petraki K, Papandreou CN, Papakostas P, Bafaloukos D, Repana D, Razis E, Pectasides D, Dimopoulos AM. Anticancer Res. 2011 Sep;31(9):3007-18. Erratum in: Anticancer Res. 2011 Oct;31(10):3637. PMID: 21868552

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilias G. Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19. PMID: 21594665

Pulmonary Langerhans cell histiocytosis in a patient previously treated for germ cell tumor. Melexopoulou CA, Sgouros J, Argyriou P, Tsitsimelis D, Aravantinos G, Samantas E. J BUON. 2010 Jan-Mar;15(1):194-5. No abstract available. PMID: 20414954

Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Pectasides D, Pectasides E, Papaxoinis G, Andreadis C, Papatsibas G, Fountzilias G, Pliarchopoulou K,

Macheras A, Aravantinos G, Economopoulos T. *Gynecol Oncol*. 2009 Oct;115(1):97-101. doi: 10.1016/j.ygyno.2009.06.025. Epub 2009 Jul 16. PMID: 19615725

Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. Mountzios G, Dimopoulos MA, Bamias A, Vourli G, Kalofonos H, Aravantinos G, Fountzilas G, Papadimitriou CA. *Ann Oncol*. 2009 Aug;20(8):1362-8. doi: 10.1093/annonc/mdn797. Epub 2009 May 20. PMID: 19457937

Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group. Bamias A, Aravantinos G, Kastriotis I, Alivizatos G, Anastasiou I, Christodoulou C, Gyftaki R, Kalofonos HP, Dimopoulos MA. *Urol Oncol*. 2011 Mar-Apr;29(2):189-93. doi: 10.1016/j.urolonc.2009.01.017. Epub 2009 Apr 11. PMID: 19362863

Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG). Pectasides D, Papaxoinis G, Fountzilas G, Aravantinos G, Bamias A, Pavlidis N, Kalofonos HP, Timotheadou E, Samantas E, Briasoulis E, Skarlos DV, Economopoulos T, Dimopoulos MA; Hellenic Cooperative Oncology Group. *Anticancer Res*. 2009 Feb;29(2):745-51. PMID: 19331231

Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1. Pectasides D, Papaxoinis G, Nikolaou M, Valavanis C, Aravantinos G, Fountzilas G, Tamvakis N, Pectasides E, Lekka I, Arapantoni-Dadioti P, Zizi A, Ghiconti I, Economopoulos T. *Anticancer Res*. 2009 Feb;29(2):737-44. PMID: 19331230

Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy. Christodoulou C, Dafni U, Aravantinos G, Koutras A, Samantas E, Karina M, Janinis J, Papakostas P, Skarlos D, Kalofonos HP, Fountzilas G. *Anticancer Res*. 2009 Feb;29(2):693-702. PMID: 19331224

Stage I testicular seminoma: management and controversies. Pectasides D, Pectasides E, Constantinidou A, Aravantinos G. *Crit Rev Oncol Hematol*. 2009 Jul;71(1):22-8. doi: 10.1016/j.critrevonc.2008.10.007. Epub 2008 Nov 28. Review. PMID: 19046898

Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G; Hellenic Cooperative Oncology Group (HeCOG). *Br J Cancer*. 2008 Dec 2;99(11):1775-85. doi: 10.1038/sj.bjc.6604769. Epub 2008 Nov 4. PMID: 18985033

Current management of stage I testicular non-seminomatous germ cell tumours. Pectasides D, Pectasides E, Constantinidou A, Aravantinos G. *Crit Rev Oncol Hematol*. 2009 May;70(2):114-23. doi: 10.1016/j.critrevonc.2008.07.018. Epub 2008 Sep 19. Review. PMID: 18805019

Paclitaxel, topotecan, and carboplatin in metastatic endometrial carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) study. Papadimitriou CA, Fountzilas G, Bafaloukos D, Bozas G, Kalofonos H, Pectasides D, Aravantinos G, Bamias A, Dimopoulos MA; Hellenic Co-

operative Oncology Group. *Gynecol Oncol*. 2008 Oct;111(1):27-34. doi: 10.1016/j.ygyno.2008.06.001. Epub 2008 Jul 21. PMID: 18644619

Adult granulosa cell tumors of the ovary: a clinicopathological study of 34 patients by the Hellenic Cooperative Oncology Group (HeCOG). Pectasides D, Papaxoinis G, Fountzilas G, Aravantinos G, Pectasides E, Mouratidou D, Economopoulos T, Andreadis Ch. *Anticancer Res*. 2008 Mar-Apr;28(2B):1421-7. PMID: 18505090

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP. *Breast Cancer Res Treat*. 2009 May;115(1):87-99. doi: 10.1007/s10549-008-0047-9. Epub 2008 May 16. PMID: 18483853

Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Papadimitriou CA, Bafaloukos D, Bozas G, Kalofonos H, Kosmidis P, Aravantinos G, Fountzilas G, Dimopoulos MA; Hellenic Co-operative Oncology Group. *Gynecol Oncol*. 2008 Jul;110(1):87-92. doi: 10.1016/j.ygyno.2008.03.004. Epub 2008 May 2. PMID: 18455782

A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydys in patients with breast cancer treated with high-dose epirubicin. Pectasides D, Dafni U, Aravantinos G, Timotheadou E, Skarlos DV, Pavlidis N, Gaglia A, Kalofonos HP, Fountzilas G. *Anticancer Res*. 2007 Nov-Dec;27(6C):4411-7. PMID: 18214053

Two cycles of etoposide/cisplatin cured all patients with stage I testicular seminoma: risk-adapted protocol of the Hellenic Cooperative Oncology Group. Bamias A, Aravantinos G, Deliveliotis C, Thanos A, Klouvas G, Antoniou N, Poulis I, Makatsoris T, Samantas E, Dimopoulos MA. *Urology*. 2007 Dec;70(6):1179-83. PMID: 18158042

Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. Onyenadum A, Gogas H, Markopoulos C, Bafaloukos D, Aravantinos G, Mantzourani M, Koutras A, Tzorakoelefterakis E, Xiros N, Makatsoris T, Fountzilas G, Kalofonos HP. *J Chemother*. 2007 Oct;19(5):582-9. PMID: 18073159

High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. Papadimitriou C, Dafni U, Anagnostopoulos A, Vlachos G, Voulgaris Z, Rodolakis A, Aravantinos G, Bamias A, Bozas G, Kiosses E, Gourgoulis GM, Efstathiou E, Dimopoulos MA. *Bone Marrow Transplant*. 2008 Mar;41(6):547-54. Epub 2007 Nov 19. PMID: 18026149

Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study. Briasoulis E, Fountzilas G, Bamias A, Dimopoulos MA, Xiros N, Aravantinos G, Samantas E, Kalofonos H, Makatsoris T, Mylonakis N, Papakostas P, Skarlos D, Varthalitis I, Pavlidis N. *Cancer Chemother Pharmacol*. 2008 Jul;62(2):277-84. Epub 2007 Sep 28. PMID: 17901952

Kit expression in male germ cell tumors. Nikolaou M, Valavanis C, Aravantinos G, Fountzilas G, Tamvakis N, Lekka I, Arapantoni-Dadioti P, Zizi A, Ghiconti I, Economopoulos T, Pectasides D. *Anticancer Res*. 2007 May-Jun;27(3B):1685-8. PMID: 17595797

Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study. Aravantinos G, Linardou H, Makridaki D, Laiou E, Zafiropoulos A, Janninis J, Sofos G, Gikas D, Samantas E, Markantoni-Kyroudi S. *J BUON*. 2003 Apr-Jun;8(2):127-32. PMID: 17472238

Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer. Malamou-Mitsi V, Crikoni O, Timotheadou E, Aravantinos G, Vrettou E, Agnantis N, Fountzilas G. *Anticancer Res*. 2007 Mar-Apr;27(2):1157-65. PMID: 17465257

Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Pectasides D, Fountzilas G, Aravantinos G, Bamias A, Kalofonos HP, Skarlos D, Briasoulis E, Konstantara A, Economopoulos T, Dimopoulos MA. *Int J Gynecol Cancer*. 2007 Sep-Oct;17(5):1003-10. Epub 2007 Mar 15. PMID: 17367314

Molecular markers in extragonadal germ cell tumours: a matched case-control study. Pectasides D, Valavanis C, Nikolaou M, Aravantinos G, Lekka I, Skarlos D, Kalofonos Ch, Fountzilas G, Kostopoulou V, Zizi A, Economopoulos T, Arapantoni-Datioti P. *Histopathology*. 2007 Feb;50(3):394-6. No abstract available. PMID: 17257142

Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Stathopoulos GP, Malamos NA, Aravantinos G, Rigatos S, Christodoulou Ch, Stathopoulos J, Skarlos D. *Cancer Chemother Pharmacol*. 2007 Jun;60(1):123-8. Epub 2006 Nov 17. PMID: 17111119

Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D, Dimopoulos MA. *BMC Cancer*. 2006 Sep 25;6:228. PMID: 16999858

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulas V. *Br J Cancer*. 2006 Sep 4;95(5):587-92. Epub 2006 Aug 8. PMID: 16909140

Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Fountzilas G, Papakostas P, Dafni U, Makatsoris T, Karina M, Kalogera-Fountzila A, Maniadas N, Aravantinos G, Syrigos K, Bamias A, Christodoulou C, Economopoulos T, Kalofonos H, Nikolaou A, Angouridakis N, Stathopoulos G, Bafaloukos D, Pavlidis N, Daniilidis J. *Ann Oncol*. 2006 Oct;17(10):1560-7. Epub 2006 Jun 21. PMID: 16790517

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer. Onyenadum A, Gogas H, Kosmidis P, Aravantinos G, Bafaloukos D, Bacoyiannis H, Markopoulos C, Koutras A, Tzorakoelefterakis E, Makatsoris T, Fountzilas G, Kalofonos HP; Hellenic Cooperative Oncology Group. *J Chemother*. 2006 Apr;18(2):192-8. PMID: 16736889

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA. *Gynecol Oncol*. 2006 Aug;102(2):285-91. Epub 2006 Mar 3. PMID: 16516283

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Bamias A, Mouloupoulos LA, Koutras A, Aravantinos G, Fountzilas G, Pectasides D, Kastritis E, Gika D, Skarlos D, Linardou H, Kalofonos HP, Dimopoulos MA. *Cancer*. 2006 Jan 15;106(2):297-303. PMID: 16342065

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP, Sifaka V, Kosmidis P, Timotheadou E, Tsavdaridis D, Bafaloukos D, Papakostas P, Razis E, Makrantonakis P, Aravantinos G, Christodoulou C, Dimopoulos AM. *Ann Oncol*. 2005 Nov;16(11):1762-71. Epub 2005 Sep 7. PMID: 16148021

Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Aravantinos G, Fountzilas G, Kosmidis P, Dimopoulos MA, Stathopoulos GP, Pavlidis N, Bafaloukos D, Papadimitriou C, Karpathios S, Georgoulis V, Papakostas P, Kalofonos HP, Grimani E, Skarlos DV; Hellenic Cooperative Oncology Group. *Ann Oncol*. 2005 Jul;16(7):1116-22. Epub 2005 May 31. PMID: 15928071

Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Kalofonos HP, Aravantinos G, Kosmidis P, Papakostas P, Economopoulos T, Dimopoulos M, Skarlos D, Bamias A, Pectasides D, Chalkidou S, Karina M, Koutras A, Samantas E, Bacoyiannis C, Samelis GF, Basdanis G, Kalfarentzos F, Fountzilas G. *Ann Oncol*. 2005 Jun;16(6):869-77. Epub 2005 Apr 26. PMID: 15855226

Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, Klouvas G, Skarlos D; Hellenic Cooperative Oncology Group. *J Neurooncol*. 2005 Jan;71(1):61-5. PMID: 15719277

Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Gogas H, Bafaloukos D, Aravantinos G, Fountzilas G, Tsoutsos D, Panagiotou P, Frangia K, Kalofonos HP, Briasoulis E, Castana O, Polyzos A, Pectasides D, Ioannovich J; Hellenic Cooperative Oncology Group. *Cancer Invest*. 2004;22(6):832-9. PMID: 15641480

Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, Kalofonos H, Kouroussis C, Gika D, Skarlos D, Bamias A. *Gynecol Oncol*. 2004 Dec;95(3):695-700. PMID: 15581984

Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology

Group (HeCOG). Fountzilas G, Christodoulou C, Tsavdaridis D, Kalogera-Fountzila A, Aravantinos G, Razis E, Kalofonos HP, Papakostas P, Karina M, Gogas H, Skarlos D. *Cancer Invest.* 2004;22(5):655-62. PMID: 15581045

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. Bafaloukos D, Papadimitriou C, Linardou H, Aravantinos G, Papakostas P, Skarlos D, Kosmidis P, Fountzilas G, Gogas H, Kalofonos C, Dimopoulos AM. *Br J Cancer.* 2004 Nov 1;91(9):1639-44. PMID: 15494721

Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, Kalogera-Fountzila A, Gogas H, Aravantinos G, Moulopoulos LA, Economopoulos T, Pectasides D, Maniadas N, Sifaka V, Briasoulis E, Christodoulou C, Tsavdaridis D, Makrantonakis P, Razis E, Kosmidis P, Skarlos D, Dimopoulos MA. *Ann Oncol.* 2004 Oct;15(10):1517-26. PMID: 15367413

Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Linardou H, Aravantinos G, Efstathiou E, Kalofonos C, Anagnostopoulos A, Deliveliotis C, Bafaloukos D, Athanasios Dimopoulos M, Bamias A; Phase II study of Hellenic Co-operative Oncology Group. *Urology.* 2004 Sep;64(3):479-84. PMID: 15351574

Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study. Gogas H, Bafaloukos D, Ioannovich J, Skarlos D, Polyzos A, Fountzilas G, Kalofonos HP, Aravantinos G, Tsoutsos D, Panagiotou P, Frangia K, Petrakopoulou T, Pectasides D; Hellenic Cooperative Oncology Group. *Anticancer Res.* 2004 May-Jun;24(3b):1947-52. PMID: 15274382

Second line chemotherapy with 5 fluorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer. Razis E, Kosmidis P, Aravantinos G, Bakoyiannis C, Janinis J, Timotheadou H, Christodoulou C, Fountzilas G. *Cancer Invest.* 2004;22(1):10-5. PMID: 15069759

Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic Cooperative Oncology Group. Bamias A, Deliveliotis Ch, Aravantinos G, Kalofonos Ch, Karayiannis A, Dimopoulos MA; Hellenic Cooperative Oncology Group. *J Urol.* 2004 Apr;171(4):1467-70. PMID: 15017199

Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N, Skarlos D. *Ann Oncol.* 2004 Mar;15(3):493-7. PMID: 14998855

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Stathopoulos GP, Syrigos K, Polyzos A, Fountzilas G, Rigatos SK, Ziras N, Potamiannou A, Tsiakopoulos I, Androulakis N, Aravantinos G, Athanasiadis A, Papakotoulas P, Georgoulas V. *Ann Oncol.* 2004 Feb;15(2):224-9. PMID: 14760113

Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Papadimitriou CA, Fountzilas G, Aravantinos G, Kalofonos C, Mouloupoulos LA, Briassoulis E, Gika D, Dimopoulos MA; Hellenic Cooperative Oncology Group Study. *Gynecol Oncol*. 2004 Jan;92(1):152-9. PMID: 14751151

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA; Hellenic Cooperative Oncology Group. *J Clin Oncol*. 2004 Jan 15;22(2):220-8. Epub 2003 Dec 9. Erratum in: *J Clin Oncol*. 2004 May 1;22(9):1771. PMID: 14665607

Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Aravantinos G, Bafaloukos D, Fountzilas G, Christodoulou C, Papadimitriou C, Pavlidis N, Kalofonos HP, Gogas H, Kosmidis P, Dimopoulos MA. *Ann Oncol*. 2003 Jul;14(7):1094-9. PMID: 12853352

The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. Samelis GF, Skarlos D, Bafaloukos D, Kosmidis P, Anagnostopoulos A, Aravantinos G, Dimopoulos MA; Hellenic Cooperative Oncology Group. *Urology*. 2003 Jun;61(6):1211-5. PMID: 12809899

Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Stathopoulos GP, Rigatos SK, Dimopoulos MA, Giannakakis T, Foutzilas G, Kouroussis C, Janninis D, Aravantinos G, Androulakis N, Agelaki S, Stathopoulos JG, Georgoulis V; Greek Cooperative Group for Pancreatic Cancer. *Ann Oncol*. 2003 Mar;14(3):388-94. PMID: 12598343

Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Sifaka V, Vlahou I, Janinis D, Pectasides D, Pavlidis N, Fountzilas G; Hellenic Cooperative Oncology Group. *Oncology*. 2003;64(2):102-10. PMID: 12566906

The pharmacological treatment of aggressive fibromatosis: a systematic review. Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. *Ann Oncol*. 2003 Feb;14(2):181-90. Review. PMID: 12562642

Docetaxel in combination with dacarbazine in patients with advanced melanoma. Bafaloukos D, Aravantinos G, Fountzilas G, Stathopoulos G, Gogas H, Samonis G, Briassoulis E, Mylonakis N, Skarlos DV, Kosmidis P. *Oncology*. 2002;63(4):333-7. PMID: 12417787

Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials. Bacoyiannis C, Dimopoulos MA, Kalofonos HP, Nicolaidis C, Aravantinos G, Bafaloukos D, Samelis G, Onyenadum A, Kiamouris Ch, Skarlos D, Pavlidis N, Triantafillidis A, Kosmidis P; Hellenic Cooperative Oncology Group. *Oncology*. 2002;63(2):130-8. PMID: 12239447

Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients. Galani E, Sgouros J, Petropoulou C, Janinis J, Aravantinos G, Dionysiou-Asteriou D, Skarlos D, Gonos E. *Anticancer Res.* 2002 Jul-Aug;22(4):2275-80. PMID: 12174914

Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. Andreopoulou E, Andreopoulos D, Adamidis K, Fountzila-Kalogera A, Fountzilas G, Dimopoulos MA, Aravantinos G, Zamboglou N, Baltas D, Pavlidis N. *Anticancer Res.* 2002 May-Jun;22(3):1903-8. PMID: 12168891

Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Dimopoulos MA, Papadimitriou CA, Sarris K, Aravantinos G, Kalofonos C, Gika D, Gourgoulis GM, Efsthathiou E, Skarlos D, Bafaloukos D. *Gynecol Oncol.* 2002 Jun;85(3):476-82. PMID: 12051877

First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study. Pectasides D, Dimopoulos MA, Aravantinos G, Kalophonos HP, Papacostas P, Briassoulis E, Cogas E, Papadimitriou C, Skarlos D, Kosmidis P, Fountzilas G. *Anticancer Res.* 2001 Sep-Oct;21(5):3575-80. PMID: 11848526

Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Pectasides D, Aravantinos G, Kalofonos H, Kiamouris C, Bafaloukos D, Xiros N, Nicolaidis C, Visvikis A, Dimopoulos MA. *Ann Oncol.* 2001 Oct;12(10):1417-22. PMID: 11762814

First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Papakostas P, Kouroussis C, Androulakis N, Samelis G, Aravantinos G, Kalbakis K, Sarra E, Souglakos J, Kakolyris S, Georgoulis V. *Eur J Cancer.* 2001 Oct;37(15):1833-8. PMID: 11576836

Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer. Fountzilas G, Papadimitriou C, Aravantinos G, Nicolaidis C, Stathopoulos G, Bafaloukos D, Kalofonos H, Ekonomopoulos T, Skarlos D, Pavlidis N, Dimopoulos AM. *Oncology.* 2001;60(3):214-20. PMID: 11340372

Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. Fountzilas G, Papadimitriou C, Dafni U, Bafaloukos D, Skarlos D, Mouloupoulos LA, Razis E, Kalofonos HP, Aravantinos G, Briassoulis E, Papakostas P, Abela K, Gogas E, Kosmidis P, Pavlidis N, Dimopoulos MA. *J Clin Oncol.* 2001 Apr 15;19(8):2232-9. PMID: 11304776

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Stathopoulos GP, Mavroudis D, Tsavaris N, Kouroussis C, Aravantinos G, Agelaki S, Kakolyris S, Rigatos SK, Karabekios S, Georgoulis V. *Ann Oncol.* 2001 Jan;12(1):101-3. PMID: 11249034

Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma. Tsavaris N, Skarlos D, Bacoyiannis C, Aravantinos G, Kosmas C, Retalis G, Panopoulos C, Vadiaka M, Dimitrakopoulos A, Kostantinidis K, Mitropoulos D, Bougas D, Pantazopoulos D, Kosmidis P. *J Interferon Cytokine Res.* 2000 Aug;20(8):685-90. PMID: 10954911

Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Fountzilias G, Nicolaidis C, Bafaloukos D, Kalogera-Fountzila A, Kalofonos H, Samelis G, Aravantinos G, Pavlidis N. *Cancer Invest.* 2000;18(6):503-9. PMID: 10923097

Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer. Aravantinos G, Dimopoulos MA, Kosmidis P, Bafaloukos D, Papadimitriou C, Kiamouris C, Pavlidis N, Sikiotis K, Papakostas P, Skarlos DV. *Ann Oncol.* 2000 May;11(5):607-12. PMID: 10907957

Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Dimopoulos MA, Papadimitriou CA, Georgoulis V, Mouloupoulos LA, Aravantinos G, Gika D, Karpathios S, Stamatelopoulos S. *Gynecol Oncol.* 2000 Jul;78(1):52-7. PMID: 10873410

Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status. Janinis J, Efstathiou E, Panopoulos C, Samantas E, Aravantinos G, Christodoulou C, Skarlos D. *Med Oncol.* 2000 May;17(2):106-10. PMID: 10871815

Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience. Pectasides D, Economopoulos T, Kouvatseas G, Antoniou A, Zoumbos Z, Aravantinos G, Tsatalas C, Halikia A, Nikolaidis C, Kiamouris C, Pappa E, Pavlidis N, Skarlos D, Fountzilias G, Dimopoulos MA. *Oncology.* 2000 May;58(4):286-92. PMID: 10838493

Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Fountzilias G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G, Papavramidis S, Bousoulegas A, Basdanis G, Giannoulis E, Dokmetzioglou J, Katsosis C, Nenopoulou E, Karvounis N, Briassoulis E, Aravantinos G, Kosmidis P, Skarlos D, Pavlidis N. *Oncology.* 2000 Apr;58(3):227-36. PMID: 10765125

Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy. Aravantinos G, Skarlos DV, Kosmidis P, Georgoulis V, Sgouros I, Bafaloukos D, Androulakis N, Florou S, Fountzilias G. *Crit Rev Oncol Hematol.* 1999 Dec;32(3):209-19. PMID: 10633850

Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Dimopoulos MA, Bakoyannis C, Georgoulis V, Papadimitriou C, Mouloupoulos LA, Deliveliotis C, Karayannis A, Varkarakis I, Aravantinos G, Zervas A, Pantazopoulos D, Fountzilias G, Bamias A, Kyriakakis Z, Anagnostopoulos A, Giannopoulos A, Kosmidis P. *Ann Oncol.* 1999 Nov;10(11):1385-8. PMID: 10631471

Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, Genatas K, Aravantinos G, Papadimitriou C, Karabekios S, Stathopoulos GP, Georgoulas V. *J Clin Oncol*. 1999 Jun;17(6):1779-85. PMID: 10561215

Platinum-based chemotherapy of primary extragonadal germ cell tumours: the Hellenic Cooperative Oncology Group experience. Pectasides D, Aravantinos G, Visvikis A, Bakoyiannis C, Halikia A, Kalofonos C, Kosmidis P, Skarlos D, Fountzilas G. *Oncology*. 1999 Jul;57(1):1-9. PMID: 10394118

Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study. Bafaloukos D, Aravantinos G, Samonis G, Katsifis G, Bakoyiannis C, Skarlos D, Kosmidis P. *Oncology*. 1999 Apr;56(3):198-201. PMID: 10202274

First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group. Fountzilas G, Dimopoulos AM, Papadimitriou C, Kalogera-Fountzila A, Aravantinos G, Bafaloukos D, Athanassiades A, Nicolaidis C, Keramopoulos A, Pavlidis N, Kosmidis P, Skarlos D. *Ann Oncol*. 1998 Sep;9(9):1031-4. PMID: 9818080

Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes. A feasibility study. Fountzilas G, Nicolaidis C, Aravantinos G, Skarlos D, Kosmidis P, Papakostas P, Stathopoulos GP, Kontostolis E, Bafaloukos D, Pavlidis N. *Oncology*. 1998 Nov-Dec;55(6):508-12. PMID: 9778614

Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Dimopoulos MA, Papadopoulou M, Andreopoulou E, Papadimitriou C, Pavlidis N, Aravantinos G, Aspropotamitis A, Anagnostopoulos A, Fountzilas G, Michalas S, Pectacides D. *Gynecol Oncol*. 1998 Jul;70(1):70-4. PMID: 9698477

Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer. Fountzilas G, Athanassiades A, Papadimitriou V, Dimopoulos MA, Bafaloukos D, Aravantinos G, Nicolaidis C, Kalofonos H, Papakostas P, Xiros N, Razi E. *Oncology (Williston Park)*. 1998 Jan;12(1 Suppl 1):45-8. PMID: 9516604

Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group. Fountzilas G, Athanassiadis A, Kalogera-Fountzila A, Aravantinos G, Bafaloukos D, Briasoulis E, Dombros N, Ioannidis I, Pavlidis N, Kosmidis P, Skarlos D. *Eur J Cancer*. 1997 Oct;33(11):1893-5. PMID: 9470853

Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, Constantinidis C, Kostakopoulos A, Kastriotis I, Zervas A, Aravantinos G, Dimopoulos C. *Urology*. 1997 Nov;50(5):754-8. PMID: 9372887

161.

Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic

Cooperative Oncology Group study. Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karpathios S, Papakostas P, Bamia C, Fountzilas G. *Semin Oncol*. 1997 Oct;24(5 Suppl 15):S15-57-S15-61. PMID: 9346224

Baldness and other correlates of sex hormones in relation to testicular cancer. Petridou E, Roukas KI, Dessypris N, Aravantinos G, Bafaloukos D, Efraimidis A, Papacharalambous A, Pektasidis D, Rigatos G, Trichopoulos D. *Int J Cancer*. 1997 Jun 11;71(6):982-5. PMID: 9185701

5-Fluorouracil, interferon-alpha-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study. Hellenic Co-operative Oncology Group. Kosmidis PA, Bacoyiannis C, Fountzilas G, Aravantinos G, Tsavaris N, Milathianakis C, Skarlos D. *Ann Oncol*. 1997 Apr;8(4):373-8. PMID: 9209668

Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study. Skarlos DV, Aravantinos G, Linardou E, Kostakopoulos CA, Kastriotis I, Christodoulou C, Picramenos D, Giannakakis T, Dimopoulos K, Fountzilas G. *Eur Urol*. 1997;31(4):420-7. PMID: 9187901

A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study. Aravantinos G, Skarlos DV, Kosmidis P, Athanassiades A, Bafaloukos D, Giannakakis T, Karpathios S, Fountzilas G. *Eur J Cancer*. 1997 Jan;33(1):160-3. PMID: 9071916

Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study. Skarlos DV, Aravantinos G, Kosmidis P, Pavlidis N, Gennatas K, Beer M, Mylonakis N, Makrantonakis P, Klouvas G, Karpathios S, Linardou H, Konstantaras C, Fountzilas G. *Eur J Cancer*. 1996 Mar;32A(3):421-8. PMID: 8814685

Megestrol acetate in cancer patients with anorexia and weight loss. A Hellenic Co-operative Oncology Group (HeCOG) study. Skarlos DV, Fountzilas G, Pavlidis N, Beer M, Makrantonakis P, Aravantinos G, Pantelakos P, Tsavaris N, Karpasitis N, Kosmidis P. *Acta Oncol*. 1993;32(1):37-41. PMID: 8466763

Immunohistochemical and immunocytochemical study of bladder carcinomas using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1. Anagnostaki E, Skarlos D, Tamvakis N, Psaropoulou P, Blana E, Bamias A, Legaki S, Aravantinos G, Deliveliotis C, Dimopoulos K. *Br J Cancer Suppl*. 1990 Jul;10:52-6. PMID: 2200496

Intravesical interferon alfa-2b administration in the treatment of superficial bladder tumors. Kostakopoulos A, Deliveliotis C, Mavromanolakis E, Aravantinos G, Dimopoulos MA. *Eur Urol*. 1990;18(3):201-3. PMID: 2261932

Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies. Malamitsi J, Skarlos D, Fotiou S, Papakostas P, Aravantinos G, Vassilarou D, Taylor-Papadimitriou J, Koutoulidis K, Hooker G, Snook D, et al. *J Nucl Med*. 1988 Dec;29(12):1910-5. PMID: 3193206

Monoclonal antibodies in ovarian tumor imaging. Fotiou S, Skarlos D, Tserkezoglou A, Aravantinos G, Malamitsi J, Koutoulidis K. *Eur J Gynaecol Oncol*. 1988;9(4):304-7. PMID: 3391206

Correlation of tissue transglutaminase expression on breast cancer tissue with time to relapse, overall survival, and clinical and molecular prognostic factors: a preliminary report. Kyparidou E, Athanasiadis A, Xydakis E, Papadaku M, Panagos G. J BUON. 2005 Jan-Mar;10(1):81-7. PMID: 17335136

Second line chemotherapy with methotrexate and gemcitabine in patients with relapsing head and neck cancer. Xydakis E, Repassos E, Poulou M, Papadaku M, Boukis C, Panagos G. J BUON. 2006 Oct-Dec;11(4):419-24. PMID: 17309172

Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma. Papadaku M, Xydakis E, Bonios M, Makropoulou E, Boukis C, Kakavoulis T, Karaliotas C, Panagos G. J BUON. 2006 Jul-Sep;11(3):285-9. PMID: 17309151

Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG). Kouroussis C, Xydakis E, Potamianou A, Giannakakis T, Kakolyris S, Agelaki S, Sara E, Malamos N, Alexopoulos A, Mavroudis D, Samonis G, Papadouris S, Georgoulis V, Panagos G. Ann Oncol. 1999 May;10(5):547-52. PMID: 10416004

A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. Giannakakis T, Kakolyris S, Theodoropoulos E, Kouroussis C, Michailakis E, Papadouris S, Tsitoura M, Kalbakis K, Souglakos J, Agelaki S, Vardakis N, Georgoulis V. Anticancer Res. 2002 Nov-Dec;22(6B):3743-8.

Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). Kouroussis C, Souglakos J, Mavroudis D, Papadouris S, Kakolyris S, Agelaki S, Kalbakis K, Panopoulos C, Vardakis N, Sarra E, Georgoulis V. Am J Clin Oncol. 2002 Dec;25(6):627-31.

Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. Kosmas C, Agelaki S, Giannakakis T, Mavroudis D, Kouroussis Ch, Kalbakis K, Papadouris S, Souglakos J, Malamos N, Georgoulis V. Oncology. 2002;62(2):103-9.

Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome. Grivas A, Lianos E, Internos I, Papaxoinis G, Tselepatiotis E, Ziras N, Athanasiou AE. J BUON. 2010 Oct-Dec;15(4):647-51.

Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. Ziras N, Potamianou A, Varthalitis I, Syrigos K, Tsousis S, Boukovinas I, Tselepatiotis E, Christofillakis C, Georgoulis V. Oncology. 2006;70(2):106-14. Epub 2006 Apr 25.